Pharmaceutical studies of Amphotericin-B : oral formulation using nanotechnology
Amphotericin B (AmB) is the gold standard treatment of systemic fungal infections. It is the secondary treatment of leishmaniasis with 97% cure rate with no reported resistance. However, the only dosage form of AmB in the market is parenteral formulations as intermittent iv infusion. Sodium deoxycho...
Main Author: | |
---|---|
Published: |
University of Newcastle upon Tyne
2016
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.697886 |